Clinical Trial Update: Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating trastuzumab in metastatic or recurrent salivary gland cancers has been terminated. The study included histologies such as mucoepiderm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Acinic Cell Carcinoma
• Salivary Gland Adenocarcinoma
• Salivary Gland Cancer
• Salivary Gland Mucoepidermoid Carcinoma
• Salivary Gland Poorly Differentiated Carcinoma

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: High-grade Salivary Gland Mucoepidermoid Carcinoma, Recurrent Salivary Gland Cancer | Phase 2 | Status: TERMINATED